Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters









Database
Type of study
Language
Publication year range
1.
[Thoughts on a favourable evolution of a COVID-19 in a patient with resistant schizophrenia and on a combination of clozapine and paliperidone palmitate]. / Réflexions autour d'une évolution favorable d'une COVID-19 chez un patient présentant une schizophrénie résistante et sous une association clozapine et palipéridone palmitate.
Bouaziz, N; Ben Rejeb, H; Ateb, S; Fourati, T; Chammas, F; Baha, D; Rosetti, R; Kalalou, K; Saba, G; Benadhira, R; Januel, D.
Encephale ; 46(3S): S126-S127, 2020 Jun.
Article in French | MEDLINE | ID: mdl-32475694

Subject(s)
Antipsychotic Agents/therapeutic use , Betacoronavirus , Clozapine/therapeutic use , Coronavirus Infections/complications , Immunologic Factors/therapeutic use , Paliperidone Palmitate/therapeutic use , Pandemics , Pneumonia, Viral/complications , Psychotic Disorders/drug therapy , Anticonvulsants/administration & dosage , Anticonvulsants/therapeutic use , Antipsychotic Agents/administration & dosage , Antipsychotic Agents/adverse effects , COVID-19 , Clozapine/administration & dosage , Clozapine/adverse effects , Delayed-Action Preparations , Drug Resistance , Drug Therapy, Combination , Humans , Immunologic Factors/administration & dosage , Immunologic Factors/adverse effects , Lithium Carbonate/administration & dosage , Lithium Carbonate/therapeutic use , Male , Middle Aged , Paliperidone Palmitate/administration & dosage , SARS-CoV-2 , Sialorrhea/chemically induced , Treatment Outcome , Valproic Acid/administration & dosage , Valproic Acid/therapeutic use
SEND TO:
Email
Export
Print
RSS
XML
SELECTION OF CITATIONS
SEARCH DETAIL